ai3Bio
ai3Bio develops therapies designed to remove disease-causing Th17 immune cells, using antibody and lipid-nanoparticle platforms to address autoimmune disease.
$48MSeries A
LeadUE
UPMC Enterprises
Activity from announced rounds
Activity in this selectionUnited States · Oct 9, 2026 · Jan 1, 2026
UPMC Enterprises is the organization identified in its own RAAPID, BrainCheck and ai3Bio materials.
Recorded funding activity
RAAPID supplies healthcare risk-adjustment software. Ai3Bio develops immune-cell-targeted medicines. The pending ai3Bio relation stays in draft, and the organization remains separate from UPMC and the University of Pittsburgh.
- Rounds participated in
- 4
- Confirmed lead rounds
- 1 3 roles undisclosed
- New companies
- 3 First participation on record · 1 follow-on
- Funding in participating rounds
- $61M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionRAAPID
Provides AI-powered risk adjustment solutions for healthcare
UndisclosedStrategic
Role not disclosedRAAPID
Provides AI-powered risk adjustment solutions for healthcare
UndisclosedSeries A+
Role not disclosedBrainCheck
Provides digital cognitive assessment and care for healthcare organizations
$13MSeries A
Role not disclosed